Globus Medical Company Profile (NYSE:GMED)

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.02. The company had revenue of $152.39 million for the quarter, compared to analyst estimates of $150.94 million. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The business's quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 earnings per share. View Globus Medical's Earnings History.

Globus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Globus Medical.

Globus Medical issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.27. The company issued revenue guidance of $625 million, compared to the consensus revenue estimate of $625.81 million.

13 brokers have issued 12 month price objectives for Globus Medical's stock. Their forecasts range from $23.00 to $38.00. On average, they expect Globus Medical's share price to reach $30.57 in the next twelve months. View Analyst Ratings for Globus Medical.

Here are some recent quotes from research analysts about Globus Medical stock:

• 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (10/4/2017)
• 2. Needham & Company LLC analysts commented, "GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth." (9/26/2017)
• 3. Barclays PLC analysts commented, "ELGX’s 2Q17 sales of $48.6M (-4.7%) came in ahead of our/consensus estimates of $47.6M; higher OUS sales offset lighter US results impacted by sales force attrition and lower AFX2 sales recapture. Ovation growth remained strong. Net loss was better on higher sales, better GM, and lower opex. ELGX lowered FY17 guidance by $9M at the midpoint to $185-190M on lower AFX2 sales recapture and sales force attrition. ELGX expects to begin PMA enrollment for Gen2 Nellix in late 2017/early 2018. We expect a slight uptick in 2H17 sales as AFX2 US softness continues, offset by Ovation US growth. We assume higher growth in ’18 versus ’17 on easier ’17 comps from both AFX manufacturing issues and the narrowed Nellix IFU." (8/3/2017)
• 4. Aegis analysts commented, "GMED reported 4Q16 non-GAAP EPS and revenues of $0.31 and $151.6 million (6.3%/6.5% cc), respectively, with EPS 2 cents short of our and consensus estimates and revenues in line with preliminary reported revenues. Gross margins for the quarter were 74.3%, down from 75.4% in 4Q15 due to one-time accounting adjustments and acquisition-related costs. Despite increasing investments, management maintained strong non-GAAP adjusted EBITDA margins of 37.7% though non-GAAP EPS fell short by 2 cents. During the call management emphasized that sales force issues are now behind them and, most importantly, that they expect to see a return to positive organic US growth in 1Q17. Management believes that this is the inflection point and is re-affirming FY2017 guidance of $625 million in revenues and $1.27 in EPS ' roughly 6.4% organic top-line growth. We believe US approval of its Excelsius GPS robot (expected by mid-year) and build out of its trauma business will provide upside to the business, where management is assuming a modest $10 million in emerging technologies contribution in 2017. We re-iterate our Buy rating and $31 TP." (2/28/2017)

Some companies that are related to Globus Medical include Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), Hill-Rom Holdings (HRC), Envision Healthcare Corporation (EVHC), United Therapeutics Corporation (UTHR), Neurocrine Biosciences (NBIX), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), HealthSouth Corporation (HLS), Juno Therapeutics (JUNO), Medidata Solutions (MDSO), Masimo Corporation (MASI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), Taro Pharmaceutical Industries (TARO), VWR Corporation (VWR) and Valeant Pharmaceuticals International (VRX).

Globus Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include St. Johns Investment Management Company LLC (0.01%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Kurt Wheeler and Robert Liptak. View Institutional Ownership Trends for Globus Medical.

Globus Medical's stock was sold by a variety of institutional investors in the last quarter, including St. Johns Investment Management Company LLC. Company insiders that have sold Globus Medical stock in the last year include A Brett Murphy and Anthony L Williams. View Insider Buying and Selling for Globus Medical.

Shares of Globus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Globus Medical stock can currently be purchased for approximately $30.65.